title: The burden of Herpes Zoster and its complications in Poland in according to the age.
abstract: BACKGROUND
  Incidence of shingles in different regions of the world ranged from 300 to 500/100,000 persons, and in the population older than 80 years of age reaches more than 1000/100,000. In the age group 50+ the incidence is enough high to be a serious medical and economic burden. Lack of details about the incidence and frequency of complications in Polish population let us too made an attempt to assess the scale of the problem, among others to the purpose of the evaluation of the legitimacy of implementing vaccination in the 50+ population.
  
  
  METHODS
  First, based on coming data from the Świętokrzyskie Province Division of the National Health Fund we judged the incidence of shingles in this province in 2013 in individual ancient groups and depending on detailed diagnoses and with the division into the basic health, clinic and hospital care. Second, based on gathered data through NIZP-PZH, we judged hospital morbidity connected with shingles in Poland in 2008-2012 years, in individual ancient groups.
  
  
  RESULTS
  Extrapolating the data from the Świętokrzyskie province we assess the incidence of shingles on average 338.8/100,000. She is tallest in the age group 50+ (614.3/100,000) and in this group also the most complications are being observed. Hospital morbidity in entire Poland showed in 2008-2012 years the frequency on average 4.93-5.42/100,000, in the group of 0-19 years; 0.10-1.50/100,000, in the group of 20-49 years; 4.9-5.42/100,000 and in the 50+ group--9.99-13.37/100,000.
  
  
  CONCLUSIONS
  (1) Shingles, especially in the 50+ age group, constitutes a serious health problem in Poland, being a cause of numerous advices in basic health care and at clinics in Poland, as well of numerous hospitalizations and dangerous complications. (2) It seems, that active immunization against shingles, especially of 50+ persons, would be a favourable solution from the individual, as well as public perspective.
authors.affiliation: Department of Paediatric Gastroenterology and Nutrition, Medical University of Warsaw.
authors.forename: Piotr
authors.initials: P
authors.lastname: Albrecht
authors.affiliation: Public Independent Healthcare Centre "Promed" in Kielce.
authors.forename: Marian
authors.initials: M
authors.lastname: Patrzałek
authors.affiliation: National Institute of Public Health, National Institute of Hygiene (NIZP-PZH), Warsaw.
authors.forename: Paweł
authors.initials: P
authors.lastname: Goryński
mesh_terms: D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs; D006562:Herpes Zoster / Q000191:economics* / Q000453:epidemiology* / Q000517:prevention & control; D053061:Herpes Zoster Vaccine / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics; D051474:Neuralgia, Postherpetic / Q000191:economics* / Q000453:epidemiology* / Q000517:prevention & control; D011044:Poland / Q000453:epidemiology; D018570:Risk Assessment
chemical_list: D053061:Herpes Zoster Vaccine